

Ovarian Cancer: Identifying and Managing Familial and Genetic Risk Committee meeting 3

Date: 14/06/2022

Location: Virtually via Zoom

Minutes: Confirmed

Committee members present:		
Alison Cameron (Chair)		(Present for notes 1 – 9)
Ranjit Manchanda (Topic Advisor)		(Present for notes 1 – 9)
Victoria Barber		(Present for notes 1 – 9)
Adam Brentnall		(Present for notes 1 – 9)
Rebecca Bowen		(Present for notes 1 – 9)
Melanie Davies		(Present for notes 5 – 9)
Gareth Evans		(Present for notes 1 – 9)
Judith Hayward		(Present for notes 1 – 8)
Tracie Miles		(Present for notes 1 – 9)
Davina Moses		(Present for notes 1 – 9)
Fiona Robb		(Present for notes 1 – 9)
Adam Rosenthal		(Present for notes 1 – 9)
Lucy Side		(Present for notes 1 – 9)
Joanne Stanford		(Present for notes 1 – 9)
Vishakha Tripathi		(Present for notes 5 – 9)

In attendance:		
Katharina Dworzynski	Guideline Lead	(Present for notes 1 – 9)
Hayley Shaw	Project Manager	(Present for notes 1 – 9)
Nathan Bromham	Senior Systematic Reviewer	(Present for notes 1 – 9)
Suhayl Kassam	Systematic Reviewer	(Present for notes 1 – 9)
Laura Berg	Systematic Reviewer	(Present for notes 1 – 9)
Eric Slade	Senior Health Economist	(Present for notes 1 – 9)
Emma Clegg	Information Scientist	(Present for notes 5 – 9)
Steve Pilling	Clinical Advisor	(Present for notes 3 – 9)

Nick Staples	Guideline Commissioning Manager	(Present for notes 1 – 9)
Helen Barnett	Senior Medical Editor	(Present for notes 1 – 4)
Apologies:		
Professor Glenn McCluggage	Committee member	
Neil Ryan	Clinical Fellow	

1. Welcome, housekeeping, aims of the day and apologies

The Chair welcomed the committee members and attendees to the 3rd meeting on Ovarian Cancer: Identifying and Managing Familial and Genetic Risk.

The Chair informed the committee that apologies had been received. These are noted above.

The Chair outlined the meeting objectives.

2. Confirmation of matter under discussion, and declarations of interest

The Chair asked everyone to verbally declare any interests that have risen since the last meeting. Four new declarations were declared as noted below:

It was confirmed that interests declared previously did not prevent the attendees from fully participating in the meeting.

Name	Role	Type of interest	Description of interest	Relevant dates			Comments
				Interest arose	Interest declared	Interest ceased	
Mrs Joanne Stanford	Lay member	Direct financial interest	Employed as Midlands Support Hub Coordinator at Ovacome, the ovarian cancer support charity. Role involves running support groups with patients, raising awareness of	May 2022	Ongoing	13/06/2022	Declare and participate. Agreed by GL and NICE CA at recruitment – February 2022 Rationale: Whilst this is a paid role and directly related to the topic there is no financial gain from this that is related to the

			the disease, answering questions about genetic testing eligibility when they arise and discussing health situations with patients. My current role is not focused on hereditary cancer but general ovarian cancer support, however the charity does produce information about hereditary cancer and genetic testing.				committee work.
Mrs Joanne Stanford	Lay member	Indirect financial interest	Employer Ovacome has received funding grants from pharmaceutical companies to support projects, including funding BRCA awareness work. This was before my time at the charity.	May 2022	Ongoing	13/06/2022	Declare and participate. Agreed by GL and NICE CA at recruitment – February 2022 Rationale: This is an indirect interest.
Dr Judith Hayward	Committee member	Direct non-financial professional and personal	Population BRCA testing Grant Yorkshire Cancer (PI Ranjit	2022	Ongoing	14.06.2022	Declare and participate. Agreed by GL and GC Chair Rationale: The committee

		interest	Manchanda)				member is not the principle investigator and there is no financial gain associated with this.
Professor Gareth Evans	Committee member	Direct non-financial professional and personal interest	Non Executive Director EverythingGenetic Ltd	May 2022	Ongoing	14/06/2022	Complete exclusion in relation to topics 4 and 5 of the scope Agreed by Chair, GL and CA Rationale: EverythingGenetic is a commercial company selling genetic tests. Non-executive board members are appointed to maximise shares and contribute to business progression. Therefore being involved in this could be perceived as having an impact on what may be recommended for the topic.
Professor Ranjit Manchanda	Topic Advisor	Direct financial interest	Non-executive Director for Everything Genetic Limited. The company EGL is involved in genetic testing which	June 2022		19/06/2022	Complete exclusion in relation to topics 4 and 5 of the scope Agreed by Chair, GL and CA Rationale: EverythingGenetic is a commercial

			<p>is both non cancer related and cancer related. It currently offers testing for COVID and multiple cancers such as breast, colorectal, prostate, urological, ovarian, haematological, etc. including testing related to cancer treatment/therapy</p> <p>I would be spending around 2-3 hours of my time, 3-4 times a year attending a board meeting. I get a small honorarium for attending a board meeting. I do not get a salary or get/hold any stocks or shares. I do not believe that my role is relevant to the scope of the guideline. The functioning of the company is completely independent of the guideline</p>				<p>company selling genetic tests. Non-executive board members are appointed to maximise shares and contribute to business progression. Therefore being involved in this could be perceived as having an impact on what may be recommended for the topic.</p>
--	--	--	---	--	--	--	--

3. Minutes of the last meeting

The Chair asked the committee to confirm the minutes of the last meeting, and the committee confirmed no changes were required.

4. Morning presentations

The Chair introduced Helen Barnett, Senior Medical Editor who delivered a presentation on the role of the editor in NICE guideline development. The Chair thanked Helen for her work.

Nathan Bromham, Senior Systematic Reviewer, presented the evidence for review question 1.2: 'Which interventions are effective for supporting women at increased risk of ovarian cancer to make decisions about management options?' The committee discussed the evidence and made some draft recommendations.

The Chair thanked Nathan for his work.

5. Lay member forum

Lay members were given the opportunity to reflect and make any suggestions or comments to the other committee members.

6. Afternoon presentations

The Chair introduced Suhayl Kassam, Systematic Reviewer, who presented the protocol for draft review question 8.3: What are the benefits and risks of hormone replacement therapy after risk-reducing surgery for women at increased risk of familial ovarian cancer? The committee discussed part of the protocol and it will be finalised at a later committee meeting.

Eric Slade, Senior Health Economist, presented the health economic priorities to the committee and asked for volunteers to review the economic plan.:

The Chair thanked Eric for his work.

7. Questions and discussion

The committee discussed:

- The evidence and draft protocols for review question 1.2
- The review protocol for draft review question 8.3.
- Health economic priorities
-

8. Any other business and summary of actions

Katharina Dworzynski summarised the actions set at the meeting.

No other business was discussed.

The Chair closed the meeting at 16:30.

Date of next meeting: 22/07/2022

Location of next meeting: Via Zoom